No Data
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
Express News | Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the Asgct Annual Meeting
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $16
Express News | Neurogene : Increases Nomination Threshold at Which Bba Has Certain Rights to Nominate One Person as Director to 14.9% of Voting Stock
Express News | Neurogene Inc - Amends Agreement With Baker Bros to Increase Nomination Threshold - SEC Filing
Neurogene Price Target Cut to $16.00/Share From $45.00 by BMO Capital